Lyrica
Product Images NDC 54868-5494

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 54868-5494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle)

Principal Display Panel (100 mg Capsule Bottle)
FDA Label Image

Principal Display Panel (150 mg Capsule Bottle)

Principal Display Panel (150 mg Capsule Bottle)
FDA Label Image

Principal Display Panel (200 mg Capsule Bottle)

Principal Display Panel (200 mg Capsule Bottle)
This is a prescription drug label for Lyrich 26646 4P G, with an NDC number of 54868-6063-1. It was distributed by Physicians Total Care and is a 400 mg extended-release tablet. However, there seems to be some inaccurate and incomplete information in the text.*
FDA Label Image

Principal Display Panel (25 mg Capsule Bottle)

Principal Display Panel (25 mg Capsule Bottle)
FDA Label Image

Principal Display Panel (50 mg Capsule Bottle)

Principal Display Panel (50 mg Capsule Bottle)
FDA Label Image

Principal Display Panel (75 mg Capsule Bottle)

Principal Display Panel (75 mg Capsule Bottle)
The text is a logo or a phrase that reads "PHYSICIANS,| TOTAL CARE". A description cannot be generated based on this text alone.*
FDA Label Image

Figure (Lyrica 01)

Figure (Lyrica 01)
This is a medical formula to calculate the creatinine clearance rate for female patients. It involves subtracting the age of the patient from 140, multiplying the result by the patient's weight in kilograms, and multiplying that result by the serum creatinine level in mg/dL. The output is then divided by 72 and multiplied by 0.85 for female patients.*
FDA Label Image

Chemical Structure (Lyrica 02)

Chemical Structure (Lyrica 02)
FDA Label Image

Figure 1 (Lyrica 03)

Figure 1 (Lyrica 03)
FDA Label Image

Figure 2 (Lyrica 04)

Figure 2 (Lyrica 04)
FDA Label Image

Figure 3 (Lyrica 05)

Figure 3 (Lyrica 05)
FDA Label Image

Figure 4 (Lyrica 06)

Figure 4 (Lyrica 06)
FDA Label Image

Figure 5 (Lyrica 07)

Figure 5 (Lyrica 07)
This text appears to be a chart or table displaying the percentage of improvement in pain from baseline for patients who received different treatments, including Pregatalin 100 mg three times a day, Pregabalin 0 mg three times a day, and Placeta. However, the characters in the text are garbled and unreadable, making it difficult to provide a more complete description.*
FDA Label Image

Figure 6 (Lyrica 08)

Figure 6 (Lyrica 08)
FDA Label Image

Figure 7 (Lyrica 09)

Figure 7 (Lyrica 09)
FDA Label Image

Figure 8 (Lyrica 10)

Figure 8 (Lyrica 10)
FDA Label Image

Figure 9 (Lyrica 11)

Figure 9 (Lyrica 11)
FDA Label Image

Figure 10 (Lyrica 12)

Figure 10 (Lyrica 12)
FDA Label Image

Figure 11 (Lyrica 13)

Figure 11 (Lyrica 13)
The data shows the percentage of subjects who experienced improvement after taking Pregabalin compared to Placebo. The percentage of subjects who experienced improvement was 100%. Graphical data is also available for reference.*
FDA Label Image

Logo (Lyrica 14)

Logo (Lyrica 14)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.